









市場行情
/
股票
/
nasdaq-agen
/

Agenus Inc

AGEN

3.505USD

+0.065+1.89%

交易中（美東）報價延遲15分鐘

115.01M總市值

虧損本益比TTM



Agenus Inc

3.505

+0.065+1.89%

概覽公司財務分析

概覽

公司

財務

分析

關於 Agenus Inc 公司

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Agenus Inc簡介



公司代碼AGEN

公司名稱Agenus Inc

上市日期Feb 04, 2000

CEOArmen (Garo H)

員工數量316

證券類型Ordinary Share

年結日Feb 04

公司地址3 Forbes Rd

城市LEXINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02421-7305

電話17816744400

網址https://agenusbio.com/

公司代碼AGEN

上市日期Feb 04, 2000

CEOArmen (Garo H)

Agenus Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+205.07%

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

22.08K

+35.46%

Mr. Brian J. Corvese

Independent Director

4.60K

Wright (Timothy R)

Lead Independent Director

2.77K

Dr. Garo H. Armen, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

Mr. Richard Goldberg

Chief Development Officer

Dr. Steven O'Day, M.D.

Chief Medical Officer

Dr. Jennifer S. Buell, Ph.D.

Director

Ms. Susan F. Hirsch

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+205.07%

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

22.08K

+35.46%

Mr. Brian J. Corvese

Independent Director

4.60K

Wright (Timothy R)

Lead Independent Director

2.77K

Dr. Garo H. Armen, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

Mr. Richard Goldberg

Chief Development Officer

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Non-cash royalty revenue

24.83M

96.65%

Other services

526.00K

2.05%

Clinical product revenue

334.00K

1.30%

地區USD

名稱

營收

佔比

United States

25.16M

97.95%

Rest of World

526.00K

2.05%

業務

地區

業務USD

名稱

營收

佔比

Non-cash royalty revenue

24.83M

96.65%

Other services

526.00K

2.05%

Clinical product revenue

334.00K

1.30%

股東統計

更新時間: 12月20日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

7.56%

Invus Public Equities Advisors, LLC

3.13%

B. Riley Financial, Inc

2.23%

Morgan Stanley & Co. LLC

1.45%

BlackRock Institutional Trust Company, N.A.

1.38%

其他

84.26%

持股股東

佔比

The Vanguard Group, Inc.

7.56%

Invus Public Equities Advisors, LLC

3.13%

B. Riley Financial, Inc

2.23%

Morgan Stanley & Co. LLC

1.45%

BlackRock Institutional Trust Company, N.A.

1.38%

其他

84.26%

股東類型

持股股東

佔比

Investment Advisor

18.38%

Investment Advisor/Hedge Fund

4.70%

Hedge Fund

3.22%

Research Firm

2.98%

Individual Investor

1.70%

Pension Fund

0.36%

Bank and Trust

0.03%

其他

68.64%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

304

9.95M

37.38%

2025Q3

332

9.95M

41.39%

+217.92K

2025Q2

334

9.73M

47.54%

+407.61K

2025Q1

334

9.33M

45.75%

-2.82M

2024Q4

341

8.45M

52.98%

-249.79K

2024Q3

351

8.70M

54.68%

-447.45K

2024Q2

347

9.21M

64.12%

-1.91M

2024Q1

356

10.69M

65.28%

-2.98M

2023Q4

374

11.90M

61.88%

+645.94K

2023Q3

382

11.27M

62.51%

+267.62K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

2.53M

7.95%

-16.81K

-0.66%

Jun 30, 2025

Invus Public Equities Advisors, LLC

1.06M

3.34%

+564.25K

+112.85%

Jun 30, 2025

B. Riley Financial, Inc

756.96K

2.38%

+756.96K

Dec 31, 2024

Morgan Stanley & Co. LLC

719.75K

2.26%

+350.35K

+94.84%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

489.68K

1.54%

-1.12M

-69.54%

Jun 30, 2025

BofA Global Research (US)

420.68K

1.32%

+220.33K

+109.97%

Jun 30, 2025

Armen (Garo H.)

338.69K

1.06%

+7.51K

+2.27%

Sep 19, 2025

Millennium Management LLC

504.51K

1.58%

+504.51K

Jun 30, 2025

Geode Capital Management, L.L.C.

317.41K

-226.73K

-41.67%

Jun 30, 2025

Walleye Capital LLC

198.29K

0.62%

+198.29K

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

iShares Russell 3000 ETF

Invesco NASDAQ Future Gen 200 ETF

Fidelity Enhanced Small Cap ETF

iShares Core S&P Total U.S. Stock Market ETF

Schwab U.S. Small-Cap ETF

SPDR Portfolio MSCI Global Stock Market ETF

Global X Russell 2000 ETF

Virtus LifeSci Biotech Clinical Trials ETF

iShares Micro-Cap ETF

佔比0.02%

iShares Russell 2000 Growth ETF

佔比0%

iShares Russell 3000 ETF

佔比0%

Invesco NASDAQ Future Gen 200 ETF

佔比0%

Fidelity Enhanced Small Cap ETF

佔比0%

iShares Core S&P Total U.S. Stock Market ETF

佔比0%

Schwab U.S. Small-Cap ETF

佔比0%

SPDR Portfolio MSCI Global Stock Market ETF

佔比0%

Global X Russell 2000 ETF

佔比0%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

公告日期

類型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

常見問題

Agenus Inc的前五大股東是誰？



Agenus Inc的前五大股東如下：
The Vanguard Group, Inc.
持有股份：2.53M
佔總股份比例：7.95%。
Invus Public Equities Advisors, LLC
持有股份：1.06M
佔總股份比例：3.34%。
B. Riley Financial, Inc
持有股份：756.96K
佔總股份比例：2.38%。
Morgan Stanley & Co. LLC
持有股份：719.75K
佔總股份比例：2.26%。
BlackRock Institutional Trust Company, N.A.
持有股份：489.68K
佔總股份比例：1.54%。